Introduction
============

Genome-wide association studies have found strong evidence for association between schizophrenia and a number of genetic variants, both common and rare.^[@bib1]^ So far, the evidence for rare variants comes mainly from the analysis of deletions and duplications of segments of DNA known as copy number variants (CNVs). Cumulatively, as a general class, large (\>100 kb) rare (\<1%) CNVs occur more frequently in those with schizophrenia^[@bib2],\ [@bib3]^ than controls, and several individual CNV loci have been strongly implicated as risk factors for schizophrenia with high degrees of statistical confidence. These include deletions at 1q21.1, *NRXN1*, 3q29, 15q11.2, 15q13.3, 22q11.2 and duplications at *VIPR2*, 16p11.2, 16p13.1 and 15q11-q13.^[@bib2],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13]^ Pleiotropic effects are common, the same CNV often conferring risk for a range of neurodevelopmental phenotypes including autism, mental retardation, attention deficit hyperactivity disorder and epilepsy, although interestingly, and in contrast to the findings with common risk alleles, there is little evidence that schizophrenia-associated CNVs confer risk for bipolar disorder.^[@bib14]^

All of the currently known risk CNVs are rare (control frequencies typically \<0.001) and confer substantial effects on risk (odds ratios 3--30). The known risk CNVs occur in 2--3% of cases, but it is likely that many other risk CNV loci remain to be identified. Most schizophrenia-associated CNVs span multiple genes, limiting our ability to make strong inferences regarding pathogenesis. Important exceptions are deletions of *NRXN1*, encoding the presynaptic neuronal cell adhesion molecule neurexin 1,^[@bib11],\ [@bib15]^ pointing to the importance of as yet unspecified abnormalities of synaptic function in the disorder. Also, obscuring mechanistic insights from the CNV data are that most reported CNVs occurring in cases are too rare to allow clear demonstration of association statistically. One way to circumvent this is to test whether particular functionally related groups or sets of genes are enriched among case CNVs, rather than trying to interpret the results from individual CNVs. A limitation of this approach is that the enrichment of CNVs seen in case--control studies is modest;^[@bib2]^ indeed, one large study has reported no overall excess of CNVs in cases at all.^[@bib4]^ This implies that among sets of CNVs drawn from cases, only a small proportion can be expected to be true risk factors for the disorder. Nevertheless, gene-set enrichment studies have supported conclusions drawn from consideration of genes affected by individual CNVs in schizophrenia^[@bib16]^ by observing enrichment in schizophrenia of genes involved in a range of brain functions, for example, those encoding products involved in nitric oxide signalling, synaptic long-term potentiation and glutamate receptor signalling,^[@bib17]^ or genes in a broad category corresponding to the gene ontology (GO) category 'synaptic transmission\'.^[@bib18]^ However, it has been noted that the early gene-set studies did not allow for important confounders, in particular the large size of genes implicated in brain function, and that the conclusions that can be drawn are consequently unclear.^[@bib19]^

Schizophrenia is associated with reduced fecundity, ∼40% that of the general population,^[@bib20]^ or even lower according to the largest population-based study.^[@bib21]^ It follows that schizophrenia-related mutations of large effect should be rare because of intense purifying selection, and those that occur in multiple unrelated individuals are likely to do so through independent *de novo* mutations.^[@bib7],\ [@bib22],\ [@bib23],\ [@bib24]^ One study on *de novo* CNV mutation in schizophrenia^[@bib24]^ showed that the rate of *de novo* CNV mutation in probands with no family history was 8 times higher in cases than in controls. This marked elevation in the rate of *de novo* CNVs contrasts with the relatively modest elevation in the rate of CNVs seen in case--control studies,^[@bib2],\ [@bib4]^ and suggests that sets of *de novos* might be more informative for gene-set enrichment analyses.

Here, we report the largest analysis of *de novo* CNVs in schizophrenia to date. Our aims were to identify novel CNVs that increase risk of schizophrenia and to illuminate aspects of the pathophysiology of the disorder through gene-set enrichment analyses informed by recently curated proteomics data sets of synaptic protein complexes.

Materials and methods
=====================

Samples
-------

### Bulgaria

The sample for *de novo* CNV analysis comprised 662 Bulgarian parent--proband trios from 638 families. We did not exclude probands (*N*=61) with a history of psychosis in a parent as none of the risk CNVs identified to date are sufficiently penetrant to fully explain the disorder in carriers. All cases had been hospitalised and met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-fourth edition) criteria for schizophrenia or schizoaffective disorder based upon SCAN (Schedules for Clinical Assessment in Neuropsychiatry) interview by psychiatrists, and review of case notes. Cases were recruited from general adult psychiatric services and were typical of those attending those services. Although they did not have formal IQ assessments, all attended mainstream schools from which people with known mental retardation were excluded. All participants provided informed consent. Further details concerning ascertainment and diagnostic practices are provided in the [Supplementary Material](#sup1){ref-type="supplementary-material"}. All DNA samples were derived from peripheral venous blood.

### Icelandic control *de novos*

deCODE Genetics provided data for 2623 complete parent--offspring trios from the Icelandic population.^[@bib7]^ Probands known to be affected with neurodevelopmental/psychiatric disorders (schizophrenia, autism, attention deficit hyperactivity disorder, mental retardation and bipolar affective disorder) had been excluded.

### Autism case and control *de novos*

Data on *de novo* rates in autism cases and their unaffected siblings are directly taken from the recent large study of Sanders *et al.*^[@bib25]^ based upon the Illumina (San Diego, CA, USA) 1M high-density array.

### Case--control data sets

We used four large publicly available data sets to which we also had access to the raw data. (1) The International Schizophrenia Consortium (ISC),^[@bib2]^ which included 3391 cases and 3181 controls genotyped with Affymetrix 6.0 or 5.0 arrays (Affymetrix, Santa Clara, CA, USA). Note that 328 Bulgarian cases from that study are probands in our trios (although their parents were not genotyped for *de novo* calling in the ISC study). We excluded those subjects from the ISC data. The ISC also included 605 unrelated controls recruited by us in Bulgaria (details in ref. [@bib2]) and those publicly available data were included in the present study. (2) The Molecular Genetics of Schizophrenia (MGS) Consortium,^[@bib4]^ which included 3192 cases and 3437 controls genotyped with Affymetrix 6.0 arrays. (3) A UK case--control study of 471 schizophrenia and 2792 controls genotyped using the Affymetrix (Affymetrix) GeneChip500K Mapping Array (see ref. [@bib3] for details of the sample and CNV calling). (4) CNV data reported by Ikeda *et al.*^[@bib26]^ comprising a Japanese sample of 519 cases and 513 controls. Including the data from the current study on transmissions and non-transmissions to affected offspring, and excluding the 328 overlapping Bulgarian cases, the combined case--control data sets contain a total of 7907 independent cases and 10 585 controls.

Genotyping and CNV analysis
---------------------------

### Bulgarian samples

Full details are provided in the [Supplementary Material (Sections 1--3)](#sup1){ref-type="supplementary-material"}. All participants were genotyped with Affymetrix 6.0 arrays (Affymetrix) at the Broad Institute of Harvard and Massachusetts Institute of Technology. As an initial screen, we used Genotyping Console 4.0 software (Affymetrix, Santa Clara, CA, USA) to call autosomal CNVs, restricting initial calls to ⩾10 kb and ⩾10 probes. We next excluded individuals with \>50 CNV calls, as these were outliers from the distribution, followed by CNV loci with a frequency \>1% in the whole sample. We then excluded putative CNVs \<15 kb, covered by \<15 probes, or where \>50% of their length overlapped low copy repeats. Calls compatible with a *de novo* were made if a proband CNV was not spanned \>50% of its length by a CNV in either parent. Probands who had large numbers of apparent *de novos* (\>10) were excluded. After this initial screen with relaxed criteria to capture as many potential *de novos* as possible, we measured probe Log2 ratios derived from PennCNV.^[@bib27]^ We then used a slight modification of the MeZOD algorithm^[@bib12]^ ([Supplementary Section 3](#sup1){ref-type="supplementary-material"}) to visualise outlier signals in probands potentially indicative of *de novos* ([Figure 1](#fig1){ref-type="fig"}). Again, we used relaxed criteria, only excluding clear false positives ([Supplementary Section 3](#sup1){ref-type="supplementary-material"}). For those whose patterns were either highly suggestive of a *de novo* (*N*=40, [Figure 1a](#fig1){ref-type="fig"}) or were ambiguous (*N*=33, [Figure 1b](#fig1){ref-type="fig"}), proband and parent DNAs were examined on custom Agilent SurePrint G3 Human CGH Microarrays on which 50--200 probes were placed to cover each CNV (depending on CNV size). For quality control purposes, we also included probes on all putative *de novos* identified by the first-pass Genotyping Console analysis, but that were subsequently rejected as false positives by the MeZOD method.

To re-call CNVs in the Bulgarian controls, we used the same filtering criteria and accepted only those considered highly suggestive by the MeZOD. Although we did not validate these on Agilent arrays, our calls have a demonstrable low false positive rate (\<1%, [Supplementary Section 4](#sup1){ref-type="supplementary-material"}). This is much less than the corresponding false positive rate for *de novos* whose rarity confers more unfavourable signal-to-noise characteristics.

### Icelandic samples

These were genotyped using Illumina bead arrays (HumanHap317, HumanHap370 and HumanHap1M). BeadStudio (Illumina, San Diego, CA, USA; version 2.0) was used to call genotypes, normalise signal intensity data and establish the log R ratio and B allele frequency at every single-nucleotide polymorphism. Samples passing quality control were examined using PennCNV (10.1101/gr.6861907). Calls required 10 consecutive markers based upon the subset of markers present on all genotyping chips listed above (the HumanHap317 content). All putative *de novo* events were visually inspected using DosageMiner software (developed by deCODE Genetics). CNVs were excluded according to low copy repeat content and frequency as for the Bulgarian sample. This resulted in 59 CNVs, an autosomal *de novo* rate of 2.2%. Given the difference in the platforms, we undertook a number of analyses to confirm that the Icelandic *de novos* are a suitable comparator group for the case *de novos* (see Results and [Supplementary Material](#sup1){ref-type="supplementary-material"}).

### MGS/ISC/UK/Japan

MGS samples were analysed in the same way as the Bulgarian samples including MeZOD. Data for ISC^[@bib2]^ UK^[@bib3]^ and Japanese samples^[@bib26]^ were taken from the original publications, and CNVs at loci of interest were manually verified in the available raw data (further information in [Supplementary Material](#sup1){ref-type="supplementary-material"}).

### Gene set analyses

#### Sets

We collated experimentally defined proteomic data sets corresponding to the structures listed in Table 2. The details of how those gene sets were collated are provided in [Supplementary Section 10](#sup1){ref-type="supplementary-material"}. We also examined sets based upon the Gene Ontology system (GO sets) in the gene2go file available from the NCBI (National Center for Biotechnology Information) on 28 July 2010 ([Supplementary Section 11](#sup1){ref-type="supplementary-material"}).

#### Statistical approaches

A gene was considered 'hit\' if a CNV was overlapped according to the NCBI Build 36.3. Full details of mapping are given as [Supplementary Section 10](#sup1){ref-type="supplementary-material"}.

The impact of biases relating to gene-set analyses of CNVs have been discussed elsewhere.^[@bib19]^ To overcome those biases, we fitted the following logistic regression models to the combined set of case and control (or control *de novo*) CNVs and compared the change in deviance between (1) and (2). logit (pr(case))=CNV size + Total number of genes hit outside the gene set + number of genes hit in the gene set.logit (pr(case))=CNV size + Total number of genes hit outside the gene set.

Significance was assessed by one-sided test of an *excess* of genes hit in the gene set by case CNVs. The inclusion of CNV size allows for case *de novo* CNVs being larger than typical CNVs (and thus likely to hit more genes). Inclusion of the total number of genes hit outside the gene set in the regression corrects for case CNVs hitting more genes overall (regardless of function) than control CNVs. Although explicitly adjusted for in the above analysis, to confirm that the results are not due to the fact that *de novo* CNVs are more likely to hit genes, we also performed an analysis restricted to CNVs that hit genes.

We used the same method to compare the number of genes in gene sets hit by case *de novos* with those hit by (1) 1367 CNVs from the 605 Bulgarian unaffected controls (2) 59 *de novos* found in Icelandic controls and (3) 14 control *de novos* from the unaffected sibs of autism probands.^[@bib25]^ The analyses control for different sources of potential bias including array type (the Bulgarian controls) and the possibility that *de novos* have fundamentally different characteristics (other than size that is adjusted for) than control CNVs.

To investigate the impact of using 'control\' CNVs, we undertook a random placement analysis comparing the number of *de novo* CNVs hitting each gene set with that found when CNV locations were randomised, importantly ensuring that each random assignment hits at least one gene, and that the probability of a gene being hit was proportional to its length ([Supplementary Section 12](#sup1){ref-type="supplementary-material"}).

### Partitioning the signals in gene sets

Gene sets are not fully independent, for example, some members of the synaptic vesicle set (Table 2) are also members of the postsynaptic density (PSD). To determine which among overlapping sets appeared to be responsible for a gene-set enrichment, we undertook conditional regression analyses as described in [Supplementary Section 13](#sup1){ref-type="supplementary-material"}.

#### Meta-analysis of case--controls

For meta-analysis combining cases and controls from multiple studies, we included in the above regression models a "study" term added as an *N*-level factor (where *N*=number of case/control sets being combined). This makes the analysis robust to differences between studies in chip, analytic method and other study-specific factors.

Results
=======

We identified 34 confirmed *de novo* CNVs ([Table 1](#tbl1){ref-type="table"}), a rate in all cases of 5.1%. Detailed descriptions of individual *de novo* CNVs are given in [Supplementary Section 6](#sup1){ref-type="supplementary-material"} and in the Discussion section. As in an earlier study,^[@bib24]^ the *de novo* rate in those with a history of psychosis in a parent was lower (1.6%) than in those without such history (5.5%), although this was not statistically significant. Parents of probands with *de novos* were not older at the time of birth of their children than parents of probands without *de novos*: (27.8 vs 28.7 years, respectively, for fathers and 25.1 vs 25.1 years for mothers). Probands with *de novo* CNVs ([Table 1](#tbl1){ref-type="table"}) did not differ from the rest of the probands regarding age at onset (23.9 vs 23.8 years, *P*=0.9) and average school results (4.5 vs 4.7, *P*=0.5), and both sets of probands had similar numbers of children (0.52 vs 0.59, *P*=0.6). In those instances (21) where it was possible to determine the parental origin, more *de novos* occurred in the paternal (*P*=14) than the maternal (*n*=7) genome but this was not statistically significant (*P*=0.13). The nonsignificant excess of paternal *de novos* was largely attributable to CNVs that were not generated by nonallelic homologous recombination, eight such events being observed on chromosomes of paternal origin compared with two on those that were maternally derived, although this is not significantly different from chance (*P*=0.06).

In order to estimate the *de novo* CNV rate in controls for comparison with cases, we compared the case *de novo* rate with that in controls from two sources, the Icelandic population controls and the unaffected sibs from a recent large study of autism^[@bib25]^ ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). The *de novo* mutation rate in our cases was higher than in both sets of controls (2.2%, *P*=0.00015 and 1.6%, *P*=0.00008, respectively), both of which had a similar rate (*P*=0.28) despite differences in the density of markers in the control genotyping platforms.

In order to exclude the possibility that the increased *de novo* rate seen in cases reflected the different platforms^[@bib28]^ used in our cases and the control studies, we undertook sensitivity analyses. If the elevation in *de novos* in cases is an artefact of greater call sensitivity in the present study, the enrichment we observed should be biased towards smaller CNVs, larger CNVs being called reliably after exclusion of CNVs spanning complex repeat regions (as we have done).^[@bib28]^ However, relative enrichment for *de novos* among cases was similar for large *de novos* \>500 kb (2.1% vs 0.8%, *P*=0.0014) as it was for small *de novos* \<200 kb (2.3% vs 0.9%, *P*=0.0035), and the overall size distribution of case *de novos* was not shifted towards smaller CNVs ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}) compared with the control *de novos*. In general, duplications are less easily detected by microarrays than deletions. To exclude the possibility that the excess of *de novos* in cases reflects a lower sensitivity of the control platforms to detect duplications, we also examined the duplication/deletion ratios in the data sets. These were not significantly different (*P*\>0.35 for each sample), although contrary to the hypothesis of a selective loss of sensitivity to detect duplications, both sets of controls actually had a higher proportion of duplications (Icelandic=0.39, Autism controls=0.36) than the cases (0.29). Further details on the size distribution of the *de novo* CNV are given in [Supplementary Section 8](#sup1){ref-type="supplementary-material"}, and of the full sensitivity analyses in [Supplementary Section 1](#sup1){ref-type="supplementary-material"}. Finally, we note that the control rates were similar to those in our experimental group with an affected parent (who according to an earlier work^[@bib24]^ do not have elevated rates of *de novo* mutation), suggesting that technical variation between our own and other studies does not make a major impact on our conclusions.

Analysis of *de novo* loci in case--control studies
---------------------------------------------------

We examined the fully independent case--control data sets for rare CNVs at the novel loci affected by case *de novos*, including CNVs only of the same class that had been observed to have occurred as *de novos* (that is, deletions, duplications or both where relevant) ([Supplementary Section 7](#sup1){ref-type="supplementary-material"}) that intersected at least one exon of a gene (details in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Even after an extremely conservative approach of excluding all CNVs (deletions and duplications) at known schizophrenia loci represented among our *de novos* (3q29, 15q11.2, 15q13.3 and 16p11.2), we found rates of 0.4% (32/7907) in cases and 0.21% (22/10 585) in controls, a twofold enrichment (Fisher one-tailed *P*=0.012). We did not obtain evidence for association to individual CNV loci at a level that would survive correction for multiple testing (*N*=19 excluding the known schizophrenia loci, giving a Bonferroni corrected threshold of *P*=0.0025). However, nominally significant associations (*P* uncorrected \<0.05) were observed for deletions at *DLG2* (*P*=0.02) and *MSRA* (*P*=0.03), whereas the *EHMT1* locus just failed to reach this uncorrected threshold (*P*=0.055). Of interest, although not even nominally significant, we also observed an excess of CNVs in cases at two other loci known to be implicated in nonpsychiatric genomic disorders: deletions of the TAR (thrombocytopenia absent radius) region (*P*=0.11) and duplications of the WBS (Williams--Beuren syndrome) region (*P*=0.11)

Gene-set analyses
-----------------

We initially undertook gene-set analyses based upon proteomics-based annotations ([Table 2](#tbl2){ref-type="table"} and [Supplementary Section 11](#sup1){ref-type="supplementary-material"}). To avoid multiple testing involved in subgroup analysis, we present the findings for the full sample of *de novos*, although we note that exclusion of the single *de novo* in a proband with a family history of psychosis in a parent made essentially no difference to the results. Compared with Bulgarian control CNVs, we found a highly significant excess of PSD genes within case *de novos* (*P*=1.72 × 10^−6^; [Table 2](#tbl2){ref-type="table"}). As expected, the results where the analysis was restricted to CNVs hitting genes were similar to those of the primary analysis (data not shown).

Significant enrichments were also observed in presynaptic vesicle and nuclear gene sets, but not after conditioning on the PSD (*P*~min~=0.66), whereas the PSD gene set remained significantly enriched for hits after conditioning on the other sets individually (*P*~max~=5.20 × 10^−3^) or combined (*P*=0.016) ([Supplementary Section 13](#sup1){ref-type="supplementary-material"}). The most parsimonious interpretation is that our findings specifically implicate the PSD, although we cannot exclude the possibility of effects across multiple functional sets.

To explore our findings in the context of a less restricted set of classifications, we performed enrichment analyses using the GO annotation. Of all categories, 'the synapse\' (GO: 45202) was by two orders of magnitude the most significantly enriched (*P*=9.6 × 10^−9^) ([Supplementary Section 11](#sup1){ref-type="supplementary-material"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}) but most of this signal was attributable to the PSD gene set (*P*=0.049 after removing PSD genes, [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Only one subcategory of 'the synapse\' GO: 45202 was enriched after PSD genes were removed: GO: 30672 'synaptic vesicle membrane\' (*P*=0.036, [Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

Aiming to localise more specifically the source of the PSD gene-set enrichment, we tested gene sets encoding PSD components ([Table 2](#tbl2){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). Activity-regulated cytoskeleton-associated protein (ARC; *P*=3.78 × 10^−8^), *N*-methyl-[D]{.smallcaps}-aspartate receptor (NMDAR; *P*=4.24 × 10^−6^) and PSD-95 complex (*P*=1.17 × 10^−5^) genes were highly significantly enriched among the *de novos*. However, conditional analyses revealed that the relatively small ARC and NMDAR sets explained both the PSD (conditional P~PSD~=0.231) and PSD-95 (conditional P~PSD-95~=0.603) enrichments but that the enrichments in ARC and NMDAR were partially independent of each other (conditional *P*=2.17 × 10^−4^ and *P*=0.019, respectively) ([Supplementary Section 13](#sup1){ref-type="supplementary-material"}). ARC and NMDAR sets also explained most of the enrichment for *de novos* in 'the synapse\', this GO category being only marginally enriched (*P*=0.017) after those genes were removed ([Supplementary Section 11](#sup1){ref-type="supplementary-material"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). After removal of members of ARC and NMDAR sets, none of the subcategories comprising the synapse was significantly enriched except for 'synaptic vesicle membrane\' (*P*=4.22 × 10^−4^). These findings suggest enrichments in the PSD, and the great majority of that in the synapse GO gene set, is because of the enrichments in ARC and NMDAR, but that there is residual enrichment elsewhere in the synapse that is captured by 'synaptic vesicle membrane\' genes (GO: 30672).

To exclude unknown possible sources of confounding arising from the use of control CNVs, we also compared gene sets hit by *de novo* CNVs from cases with those hit in random assignments of gene-hitting CNVs of the same size, ensuring the probability of a gene being hit was proportional to its size. Again, we observed significant enrichment of PSD genes (*P*=0.0024), and a highly significant enrichment of the ARC (2.21 × 10^−8^) and NMDAR (2.95 × 10^−4^) complexes ([Supplementary Section 12](#sup1){ref-type="supplementary-material"}).

To exclude the possibility that our results reflect general properties of *de novo* CNVs, we compared case *de novo* CNVs with *de novo* CNVs identified in the control individuals from Iceland and from the Autism study by Sanders *et al.*^[@bib25]^ Despite fewer control CNVs in these samples (*N*=59 and *N*=14), and therefore reduced power, the findings were consistent with our primary analysis in showing significant enrichment of ARC and NMDAR ([Table 2](#tbl2){ref-type="table"}) as were those of sensitivity analysis restricted to very large CNVs (\>500 kb) (ARC *P*=1.27 × 10^−4^; NMDAR *P*=1.72 × 10^−2^).

Finally, we examined the ARC/NMDAR gene sets in the large case--control data sets. In this completely independent analysis, case CNVs were significantly enriched for members of the NMDAR (*P*=0.0015) but not ARC complexes (*P*=0.14). We note that in the *de novo* analysis, much of the additional signal for the ARC complex (over and above that of the NMDAR) comes from CNVs at 15q11.2 that span *CYFIP1*. Although there is strong published evidence for deletions at this locus being relevant to schizophrenia,^[@bib3],\ [@bib7]^ this locus was not significantly enriched in the MGS study,^[@bib4]^ and was excluded by the filtering criteria adopted by the ISC,^[@bib2]^ the two studies that combined comprise a large proportion of the case--control data set we use in this study.

Discussion
==========

Aiming to identify novel candidate CNV loci for schizophrenia, and to illuminate aspects of the pathophysiology of the disorder through gene-set enrichment analyses, we have conducted the largest analysis of *de novo* CNVs in schizophrenia to date. Although not every observed case *de novo* CNV is likely to be pathogenic, the hypothesis that a substantial proportion of them are likely to be so is supported by several observations. First, eight of the *de novos* occurred at already known schizophrenia CNV loci ([Table 1](#tbl1){ref-type="table"}, marked with footnote 'a\'). Second, even after conservatively excluding those known loci, CNVs at the loci affected by case *de novos* occurred twice as frequently in cases in a meta-analysis of the largest available case--control CNV data sets. This elevation is much higher than the overall increase in CNV burden in cases in the large published studies.^[@bib2],\ [@bib4]^ Third, in the trios sample, the rate of *de novo* CNVs was more than twice that observed in other control samples ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}), suggesting that at least 50% of the case *de novos* are relevant to the pathophysiology of schizophrenia.

Our estimate of the *de novo* rate is lower than initial reports in autism^[@bib23]^ and schizophrenia^[@bib24]^ but is comparable with more recent estimates in autism.^[@bib25],\ [@bib29],\ [@bib30]^ *Post hoc* evaluation suggests it is unlikely that our filtering steps excluded large numbers of true *de novo* CNVs within our target size range. Of the 34 Agilent-validated *de novos*, 91% (*N*=31) had been rated (using MeZOD) as highly suggestive, whereas only 9% (*N*=3) had been called as ambiguous. Conversely, none of 33 putative *de novos* called by the Genotyping Console that were rejected by MeZOD were confirmed by Agilent.

It is notable that two previously documented schizophrenia loci, at 15q11.2 and 15q13.3, were each found more than once as *de novos* ([Table 1](#tbl1){ref-type="table"}). Two other loci were represented by two *de novo* CNVs each: *EHMT1* (encoding Eu-HMTase1), a histone H3 Lys 9 (H3-K9) methyltransferase, and *DLG2* (encoding discs, large homologue 2). Moreover, one *de novo* spanned each of the related genes *DLG1* (whose orthologue in *Drosophila* is also *dlg1*) and *DLGAP1* (encoding discs large associated protein 1).

At *EHMT1* we observed a total of two *de novos*, three additional exonic CNVs in cases and one in a control. *EHMT1* haploinsufficieny has been implicated as the cause of the 9q subtelomeric deletion syndrome (9qSTDS) characterised by moderate-to-severe mental retardation, childhood hypotonia and facial dysmorphisms, as well as a high prevalence of psychiatric symptoms in adulthood.^[@bib31]^ A recent study has also reported strong evidence that deletions at *EHMT1* are highly penetrant for phenotypes comprising developmental delay and a range of congenital anomalies.^[@bib32]^ With this additional evidence for the involvement of this gene in neurodevelopmental phenotypes, our data point to *EHMT1* as a schizophrenia susceptibility gene. Intriguingly, in *Drosophila, ehmt* coordinates epigenetic changes important in regulating cognition.^[@bib33]^ Our findings at this locus thus suggest a role for epigenetic mechanisms in at least some cases of schizophrenia, and potentially point the way to novel therapeutic opportunities as the developmental effects of *ehmt* mutation on cognition are reversible.^[@bib31]^

The DLG (discs large) family of membrane-associated guanylate kinases (MAGUKs), which were hit by multiple case *de novo* CNVs, are components of postsynaptic signalling complexes that are embedded within the larger group of over 1000 proteins that make up the PSD.^[@bib34]^ They are associated with NMDA receptors and are highly concentrated in synapses. Remarkably, the orthologue of *DLG2* in *Drosophila* (*dlg1*) is directly regulated by the orthologue of *EHMT1* (emht also known as G9a).^[@bib33]^ CNVs spanning *DLG1* and *DLG2* have been reported before in schizophrenia^[@bib4],\ [@bib6],\ [@bib17]^ whereas other members of the family (*DLG3* and *DLGAP2*) have been implicated in mental retardation^[@bib35]^ and autism.^[@bib30],\ [@bib36]^ Together with our observation of multiple *de novos* spanning members of this family, and the nominally significant association of exonic CNVs at *DLG2* in the case-- control analysis, the findings strongly suggest that the CNVs we report in *DLG-*related genes are likely to be of pathogenic relevance to schizophrenia.

Although not strongly implicated by our study, a number of singleton *de novo* CNVs are also of note as they are at loci known to be associated with rare genomic disorders. The first is a deletion at 1q21.1 reported in TAR syndrome^[@bib37]^ (which does not overlap the known 1q21.1 schizophrenia locus^[@bib2],\ [@bib7]^). We found the TAR region deleted in three more cases and only one control from the extended case--control samples. Again, deletions at this locus have very recently been strongly implicated in developmental delay.^[@bib32]^ Another region is a duplication at the locus causing the 7q11.23 microduplication syndrome (which is deleted in Williams--Beuren Syndrome), the prominent features of which include autism and developmental delay.^[@bib38]^ Duplications at the WBS region were found in three more cases and one control. Although this excess is not statistically significant (*P*=0.11, uncorrected), given duplications at this locus have also recently been identified increasing susceptibility for autism^[@bib25]^ and developmental delay,^[@bib32]^ it seems likely that the observations in the present study point to the involvement of this locus in schizophrenia as well. Further details about each of these loci are provided in [Supplementary Section 6](#sup1){ref-type="supplementary-material"}.

Given that our data suggest *de novo* CNVs are highly enriched for pathogenic loci, we sought evidence for convergence of *de novo* events onto specific biological pathways using a hypothesis-led, systems biology approach. Many of the CNVs robustly implicated in schizophrenia are also implicated in neurodevelopmental disorders in which cognitive impairment is common.^[@bib39],\ [@bib40],\ [@bib41]^ Moreover, as discussed in the Introduction, it has been hypothesised that schizophrenia CNVs are enriched for genes encoding proteins associated with synaptic function. Our findings of apparent convergence of *de novo* CNVs onto genes encoding MAGUK proteins broadly support this synaptic hypothesis and suggested that more refined examination of synaptic genes is warranted.

Cognitive deficits are increasingly recognised as core features of schizophrenia, and it has long been known that antagonism of NMDA receptors at glutamatergic synapses can induce a schizophrenia-like psychosis that includes some of those deficits.^[@bib42]^ This has led to a glutamate hypofunction hypothesis of schizophrenia. Glutamate receptors form multiprotein complexes with large sets of scaffold and signalling proteins including MAGUKs^[@bib43]^ that are embedded in the PSD. It is clear that disruption of a number of synaptic proteins linked to glutamate receptor signalling alters cognitive function in rodents.^[@bib44]^ The composition of the PSD has recently been identified in humans by some of the present authors,^[@bib34]^ affording us an unprecedented opportunity to investigate the role of this complex in schizophrenia. Specifically, we tested the hypothesis that *de novo* CNVs in cases are enriched for genes encoding members of this complex.

We first compared the case *de novos* with a set of control CNVs drawn from the same population as the trios. Although those CNVs must have originally occurred as *de novo* mutations, predominantly transmitted CNVs clearly have different characteristics from the case *de novos*, most obviously size. Although our set-based analyses allow for size differences, to ensure our findings were robust to the control data set, we also compared gene sets hit by case *de novo* CNVs with those hit in random assignments of gene-hitting CNVs of the same size and obtained very similar gene-set enrichments. Finally, in order to exclude the possibility that our findings reflected general properties of *de novo* CNVs, we compared case *de novo* CNVs to two sets of control *de novos*, one drawn from the Icelandic population and the other from a much smaller sample of unaffected sibs of people with autism. Despite the wide disparities in the sources of the control CNVs, and the potential for different sources of bias, the results converge in pointing to the involvement of the synapse, the PSD, and more specifically, ARC and NMDAR complexes. Finally, and fully independent of those analyses, we show a significant enrichment for genes in the NMDAR complex in a meta-analysis of case--control data sets. We think it likely that the weaker finding for the NMDAR complex in the large case--control study compared with the relatively small *de novo* study, and the absence of association to ARC in the former, reflects the much lower power of the case--control design as a result of poorer enrichment for pathogenic CNVs.

This study adds to an accumulating body of evidence from human and animal genetic studies implicating disruption of synaptic processes in schizophrenia.^[@bib45]^ By identifying an unprecedentedly large number of *de novo* CNVs in schizophrenia and demonstrating that these are likely to be highly enriched for pathogenic events, we have added substantially to the evidence implicating synaptic processes in schizophrenia. As well as implicating a set of functionally related synaptic proteins (*EHMT1, DLG2, DLG1* and *DLGAP1*) we have identified a sufficient number of schizophrenia-enriched loci to identify potential points on convergence on specific synaptic complexes. Using gene sets that have been systematically annotated from individual, high-quality proteomic data sets and multiple analytic approaches carefully controlled for biases, we not only provide strong evidence for the importance of synaptic proteins, but also provide novel convergent support for the involvement of NMDAR, and to a lesser extent ARC protein, complexes in the aetiology and pathogenesis of the disorder, both of which are involved in NMDA signal transduction. NMDA receptor signalling regulates induction of multiple forms of synaptic plasticity,^[@bib46]^ with local synthesis of ARC central to synaptic remodelling and the long-term maintenance of synaptic changes.^[@bib47]^ Our finding that 12 out of the 34 case *de novos* impact on ARC and/or NMDAR complexes, supported by robust statistical analyses, suggest that disruption of NMDA signalling plays a key role in at least some cases of schizophrenia. As noted above, our findings do not exclude a role for mutations in other post- or pre-synaptic complexes, and given the close functional relationship between different synaptic components, we might expect pathology at a number of different points to play a role. Indeed, the robust association between *NRXN1* deletions and schizophrenia^[@bib48]^ points to presynaptic disruption in some cases, a hypothesis further supported by enrichment for case *de novos* in the GO category 'synaptic vesicle membrane\' after adjustment for ARC and NMDAR. Our findings delineate a circumscribed set of largely postsynaptic proteins and functions that warrant further functional analysis in model systems.
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![Histograms of distributions of *z*-scores. (**a**) A suggestive *de novo* and (**b**) an ambiguous *de novo* MeZOD call. Black arrows indicate the position of a parent, and red arrows of a child. The *x* axis shows the median *z*-scores for all individuals for a particular copy number variant (CNV) region.](mp2011154f1){#fig1}

![Size of copy number variants (CNVs). Kaplan--Meier survival graph for the size of *de novo* CNVs in cases, Icelandic controls, Bulgarian controls and unaffected siblings of autism probands.^[@bib25]^](mp2011154f2){#fig2}

![Disruption of postsynaptic signalling within activity-regulated cytoskeleton-associated protein (ARC) and *N*-methyl-[D]{.smallcaps}-aspartate receptor (NMDAR) complexes by copy number variants (CNVs). ARC and NMDAR bind to diverse structural and signalling molecules forming multiprotein complexes. Functional pathways encoded by these complexes are disrupted by *de novo* CNVs at multiple levels, as indicated by the purple asterisks (number of asterisks=number of *de novos* overlapping a gene or gene family). Calcium influx via the NMDAR, modulated by calcium release from internal stores (RYR2), drives downstream pathways whose association with the receptor is mediated by scaffold proteins (*DLG1*, *DLG2, DLGAP1*). Multiple pathways converge on ERK kinases (extracellular signal-regulated kinases), a focal point in the regulation of ARC transcription, dendritic localisation and local translation.^[@bib47]^ ARC mRNA is transported to sites of synaptic activity in complexes containing *CYFIP1*, dissociation of which is required for ARC translation.^[@bib49]^ *CYFIP1* also regulates translation of CAMKII,^[@bib49]^ a key component of NMDAR complexes. Although not identified in this study, deletions of synaptic adhesion protein NRXN1 (blue asterisk) have previously been found in schizophrenia.^[@bib29]^ CNVs disrupting genes within these same functional pathways have also been identified in autism^[@bib30]^(black asterisks).](mp2011154f3){#fig3}

###### List of *de novo* CNVs found in the study

  *Cytoband*                           *Location*                   *Type*   *Size (bp)*   *Genes*                   *Origin of mutation, F:M SNPs*   *Diagnosis*   *Schooling*              *Children*  *Age at onset/ age at sampling*   *Somatic*
  ------------------------------------ ---------------------------- -------- ------------- ------------------------- -------------------------------- ------------- ----------------------- ------------ --------------------------------- -----------------------------------------------------
  1q21.1                               chr1:144101459--144503409    Del      401 950       16 genes, TAR region      10F:0M                           SA            V good, college              2       40/49                             Psoriasis
  1q43                                 chr1:235475280--235639644    Del      164 364       *RYR2*                    12F:0M                           SZ, par       Good                        ---      21/33                             Patent ductus arteriosus[b](#t1-fn3){ref-type="fn"}
  2q21.2                               chr2:133504420--133879778    Del      375 358       *NAP5*                    7F:0M                            SZ, par       V good                       1       18/25                             ---
  3q13.12                              chr3:109330592--110198715    Dupl     868 123       9 genes                   11F:0M                           SZ, cat       Pass                         2       33/48                             ---
  3q29[a](#t1-fn2){ref-type="fn"}      chr3:197185548--198825231    Del      1 639 683     21 genes, 3q29 syndrome   56F:0M                           SZ, par       Good, college               ---      19/45                             Congenital heart disease
  4q13.3                               chr4:70935504--70969553      Del      34 049        *HTN1, HTN3*              ---                              SZ, cat       Excellent, college          ---      24/33                             ---
  4q21.21                              chr4:79944612--80081979      Del      137 367       *BMP2K, PAQR3*            ---                              SZ, par       Excellent                    1       32/33                             ---
  6q12                                 chr6:68675955--68761101      Dupl     85 146        ---                       ---                              SZ, par       Excellent                   ---      23/29                             Hypertension
  7p14.1                               chr7:38260614--38307187      Del      46 573        TARP                      ---                              SA            Excellent, university       ---      17/24                             Asthma
  7q11.23                              chr7:72390286--76445231      Dupl     4 054 945     38 genes, WBS region      1F: 45M                          SZ, dis       V good                      ---      17/28                             ---
  7q32.1                               chr7:127275795--127447967    Del      172 172       C7orf54, SND1             ---                              SA            V good                      ---      25/35                             ---
  8p23.2                               chr8:4121968--4299810        Del      177 842       *CSMD1*                   0F:23M                           SZ, par       Excellent, university       ---      17/37                             ---
  8p23.1                               chr8:10066862--10155414      Del      88 552        *MSRA*                    ---                              SZ, par       Pass                        ---      15/41                             ---
  9p22.3                               chr9:16310745--16327782      Del      17 037        ---                       ---                              SA            Excellent, university        1       34/37                             ---
  9q31.3                               chr9:110859131--111433199    Dupl     574 068       4 genes                   ---                              SZ, ns        Pass                        ---      9/26                              ---
  9q34.3                               chr9:139762152--139797423    Dupl     35 271        *EHMT1*                   ---                              SZ, ns        V good                       2       20/37                             Overweight
  9q34.3                               chr9:139769564--139792102    Del      22 538        *EHMT1*                   ---                              SZ, dis       Pass                         1       24/36                             Overweight
  11q14.1                              chr11:83472750--83842973     Del      370 223       *DLG2*                    0F:M12                           SZ, cat       V good, college             ---      18/22                             ---
  11q14.1                              chr11:84006106--84226064     Del      219 958       *DLG2*                    10F:0M                           SZ, par       Pass                         2       20/35                             ---
  12q24.13                             chr12:111723795--111776045   Del      52 250        *RPH3A*                   ---                              SZ, par       Good                        ---      21/33                             Patent ductus arteriosus[b](#t1-fn3){ref-type="fn"}
  12q24.33                             chr12:130388037--130659530   Dupl     271 493       ---                       ---                              SZ, par       Good                        ---      27/33                             ---
  13q14.11                             chr13:40319620--41182276     Del      862 656       8 genes                   15F:0M                           SZ, par       Good                        ---      22/33                             ---
  14q13.2                              chr14:34464771--34627720     Del      162 949       3 genes                   1F:0M                            SA, FH+       Excellent                   ---      16/24                             ---
  15q11.2[a](#t1-fn2){ref-type="fn"}   chr15:19548923--20852202     Del      1 303 279     8 genes                   0F:16M                           SZ, par       Pass                        ---      32/42                             ---
  15q11.2[a](#t1-fn2){ref-type="fn"}   chr15:20224751--20777909     Dupl     553 158       5 genes                   0F:10M                           SA            Pass                         1       20/28                             ---
  15q11.2[a](#t1-fn2){ref-type="fn"}   chr15:20224751--20852202     Dupl     627 451       5 genes                   0F:8M                            SA            Good                        ---      29/31                             ---
  15q11.2[a](#t1-fn2){ref-type="fn"}   chr15:20302446--21038975     Del      736 529       6 genes                   19F:0M                           SZ, par       V good                       1       17/28                             ---
  15q13.1                              chr15:26785056--28289366     Dupl     1 504 310     4 genes                   0F:2M                            SZ, dis       Pass                        ---      23/43                             ---
  15q13.3[a](#t1-fn2){ref-type="fn"}   chr15:28707904--30326817     Del      1 591 596     7 genes                   93F:0M                           SZ, par       Pass                        ---      31/38                             ---
  15q13.3[a](#t1-fn2){ref-type="fn"}   chr15:28707904--30299500     Del      1 618 913     7 genes                   25F:0M                           SZ, par       V good                      ---      32/52                             ---
  16p11.2[a](#t1-fn2){ref-type="fn"}   chr16:29488112--30099396     Dupl     611 284       31 genes                  21F:0M                           SZ, par       Excellent, college           1       35/46                             Rheumatoid arthritis
  18p11.31                             chr18:3515935--4332609       Del      816 674       *DLGAP1, FLJ35776*        61F:0M                           SZ, par       Good                         1       18/25                             ---
  20p12.1                              chr20:14694326--14863051     Del      168 725       *MACROD2*                 2F:0M                            SZ, cat       V good                       1       32/37                             ---
  21q21.1                              chr21:22698250--22778244     Del      79 994        ---                       ---                              SA            Excellent, university       ---      29/30                             Single febrile convulsion

Abbreviations: CNV, copy number variant; SA, schizoaffective disorder; SNP, single-nucleotide polymorphism; SZ, cat, catatonic schizophrenia; SZ, dis, disorganised schizophrenia; SZ, ns=schizophrenia, not otherwise specified; SZ, par, paranoid schizophrenia; TAR thrombocytopenia absent radius; WBS, Williams--Beuren syndrome.

Indicates a known schizophrenia locus.

Same patient who has two *de novos*.

Origin of mutation indicates whether the mutation had occurred on the paternal or maternal chromosome. The number of informative SNPs supporting parental origin are given in the order father(F):mother(M). Additional detail is given in [Supplementary Section 6](#sup1){ref-type="supplementary-material"}. Coordinates in the paper refer to the UCSC (University of California, Santa Cruz) human genome assembly hg18 (National Center for Biotechnology Information (NCBI) build 36). Final school results in Bulgaria are reported as 2=fail, 3=pass, 4=good, 5=very good, 6=excellent.

###### Enrichment of gene sets for *de novo* CNV hits in comparison with control CNVs

  *Gene set*                                     N *genes*   N *genes hit by CNVs* P*-value*   *Genes hit by SCZ* de novos                                            
  ---------------------------------------------- ----------- --------------------------------- ----------------------------- ----------------------- ---------------- -----------------------------------------------------------------------------------------------------------------------------------
  PSD                                            664         19                                49 (**1.72 × 10^−6^**)        13 (**0.045)**          4 (0.11)         *DLG1, DLG2, DLGAP1, RYR2, SND1, **STX1A**, **MDH2**, HSPB1, **YWHAG**, **RPH3A**, **CYFIP1**, **TJP1**, **ALDOA**, TAOK2, MAPK3*
   ARC complex                                   25          8                                 7 (**3.78 × 10^−8^**)         1 (**2.51 × 10^−4^**)   0 (**0.0049)**   *DLG1, DLG2, DLGAP1, CYFIP1*
   NMDAR complex                                 59          8                                 6 (**4.24 × 10^−6^**)         2 (**0.0061)**          0 (**0.01)**     *DLG1, DLG2, DLGAP1, STX1A, YWHAG, TJP1, MAPK3*
   PSD-95 complex                                58          4                                 3 (**1.17 × 10^−5^**)         1 (**0.017)**           0 (**0.033)**    *DLG1, DLG2, DLGAP1*
   mGluR5 complex                                37          3                                 4 (**0.026)**                 2 (0.45)                0 (0.15)         *YWHAG, RPH3A, ALDOA*
  Presynapse                                     426         8                                 25 (**0.033)**                8 (0.32)                2 (0.28)         ***STX1A, RPH3A, CYFIP1, ALDOA, MDH2***
   Synaptic vesicle                              333         7                                 20 (**0.014)**                8 (0.39)                2 (0.31)         *STX1A, RPH3A, CYFIP1, ALDOA*
   Active zone                                   176         2                                 6 (0.29)                      3 (0.91)                0 (0.26)         *ALDOA, MDH2*
  Nucleus                                        160         5                                 10 (**0.0024)**               2 (**0.026)**           0 (**0.018)**    ***CYFIP1**, **TJP1***
  Mitochondrion                                  189         3                                 9 (0.41)                      1 (0.11)                0 (0.093)        ***MDH2**, BDH1, KIAA0564*
  Cytoplasm                                      263         4                                 11 (0.68)                     3 (0.55)                0 (0.15)         *EIF4H, **YWHAG**, MSRA, MVP*
  Endoplasmic reticulum                          94          1                                 3 (0.75)                      0 (0.18)                0 (0.31)         *POR*
  Endoplasmic reticulum/Golgi-derived vesicles   94          0                                 0                             0                       0                 
  Recycling endosomes                            65          0                                 2 (0.83)                      0                       0                 
  Early endosomes                                17          0                                 1 (0.82)                      0                       0                 
  Golgi                                          31          0                                 1 (0.82)                      0                       0                 
  Plasma membrane                                50          0                                 2 (0.61)                      0                       0                 

Abbreviations: ARC, activity-regulated cytoskeleton-associated protein; CNV, copy number variant; NMDAR, *N*-methyl-[D]{.smallcaps}-aspartate receptor; PSD, postsynaptic density; SCZ, schizophrenia. Gene sets were tested for enrichment in 34 schizophrenia ('SCZ\') *de novo* CNVs compared with 1367 CNVs found in 605 Bulgarian controls ('controls\'), 59 *de novo* CNVs found in 2623 unaffected individuals from the Icelandic population ('Icelandic control *de novo\'*) and 14 *de novo* CNVs found in unaffected siblings of autism proband from the study by Sanders *et al.*^[@bib25]^ ('Autism control *de novo*\'). '*N* genes\' refers to number of genes in the set. *P*-values are presented underneath the number of genes hit and correspond to one-tailed tests of an excess of gene hits in case CNVs. *P*-values in bold are significant. '*N* genes hit by CNVs\' refers to the number of times any gene in the set is hit by a CNV. The unique genes hit in each set are given in the final column. Genes in bold are present in multiple subcellular components.
